Quotient (QTNT) Stock Forecast, Price & News

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Quotient in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Quotient stock.
View analyst ratings for Quotient or view top-rated stocks.

4 brokers have issued twelve-month price objectives for Quotient's stock. Their QTNT stock forecasts range from $1.50 to $3.00. On average, they expect Quotient's share price to reach $2.25 in the next year. This suggests a possible upside of 804.0% from the stock's current price.
View analysts' price targets for Quotient or view top-rated stocks among Wall Street analysts.

Quotient's stock was trading at $2.59 on January 1st, 2022. Since then, QTNT shares have decreased by 90.4% and is now trading at $0.2489.
View the best growth stocks for 2022 here.

Quotient saw a decrease in short interest during the month of July. As of July 15th, there was short interest totaling 2,680,000 shares, a decrease of 38.5% from the June 30th total of 4,360,000 shares. Based on an average trading volume of 2,290,000 shares, the days-to-cover ratio is currently 1.2 days.
View Quotient's Short Interest.

Quotient is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for Quotient.

Quotient will be holding an earnings conference call on Tuesday, August 9th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Quotient Limited (NASDAQ:QTNT) issued its quarterly earnings data on Friday, June, 24th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.09. During the same quarter in the prior year, the business earned ($0.39) earnings per share.

Quotient issued an update on its FY 2023 earnings guidance on Friday, July, 22nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $39.00 million-$42.00 million, compared to the consensus revenue estimate of $40.25 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quotient investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Verastem (VSTM), Cidara Therapeutics (CDTX), Dynavax Technologies (DVAX), Gilead Sciences (GILD), SCYNEXIS (SCYX), Novavax (NVAX), Ocular Therapeutix (OCUL) and Sorrento Therapeutics (SRNE).

Quotient trades on the NASDAQ under the ticker symbol "QTNT."

Shares of QTNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QTNT stock can currently be purchased for approximately $0.25.

Quotient (NASDAQ:QTNT) has a market capitalization of $25.69 million and generates $38.51 million in revenue each year. The company earns $-125,130,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis.

Quotient employs 426 workers across the globe.

Quotient's mailing address is B1 Business Park Terre Bonne Route de Crassier 13, Eysins Y9, 1262. The official website for Quotient is www.quotientbd.com. The company can be reached via phone at (122) 716-9800 or via email at ir@quotientbd.com.